丹红注射液对急性大面积脑梗死患者MMP-9、Hs-CRP及NIHSS评分的治疗观察

Efficacy of the Danhong injection on MMP-9, Hs-CRP and NIHSS scores of patients with the acute large area cerebral infarction

目的:观察丹红注射液对急性大面积脑梗死患者血清基质金属蛋白酶-9(MMP-9)和超敏C反应蛋白(Hs-CRP)的影响及对神经功能缺损(采用美国国立卫生研究院神经功能缺损评分,即NIHSS)的治疗作用。方法:将急性大面积脑梗死患者126例随机分为对照组和治疗组,分别测定两组治疗前后MMP-9、Hs-CRP的量及NIHSS评分,比较两组MMP-9、HsCRP及NIHSS评分改善的程度。结果:一个疗程(10d)结束后,对照组MMP-9、Hs-CRP、NIHSS评分分别下降159.86μg/L、11.49mg/L、12.8分,治疗组分别下降199.62μg/L、15.72mg/L、20.8分,经统计学处理治疗组均明显优于对照组。结论:丹红注射液能显著降低大面积脑梗死患者血清MMP-9、Hs-CRP的含量,改善神经功能缺损,有效治疗急性大面积脑梗死。

Objective： To observe efficacy of the Danhong injection on MMP-9, Hs-CRP and NIHSS scores of patients with the acute large area cerebral infarction. Methods： 126 patients were divided into the control group and the treatment group. MMP-9, Hs-CRP and NIHSS scores in groups were compared. Results： In 10 days, MMP-9, Hs-CRP and NIHSS score were fallen by 159.86μg/L, 11.49mg/L and 12.8 respectively in the control group, and better than 199.62μg/L, 15.72mg/L and 20.8 respectively in the treatment group （P〈0.05）. Conclusion： The Danhong injection on the acute large area cerebral infarction could decrease MMP-9, Hs-CRP and NIHSS scores, and is effective on the disease.